title: The influence of hyperprolactinemia on coagulation parameters in females with prolactinomas.
abstract: BACKGROUND
  Currently there is little information on the effects of prolactin (PRL) on the coagulation and fibrinolytic systems.
  
  
  OBJECTIVE
  The aim of this study was to evaluate the effects of hypeprolactinemia on the parameters of the hemostatic system and activation of the coagulation system.
  
  
  METHODS
  We studied PRL levels, body mass index (BMI), values of activated partial thromboplastin time (aPTT), prothrombin time (PT), thrombin time (TT), D-dimer level, von Willebrand factor antigen (vWFAg) and fibrinogen in 15 young female patients with microprolactinomas before and after therapy and in 15 healthy female controls.
  
  
  RESULTS
  As expected, pretreatment PRL levels were significantly higher in patients than in controls (140.90 +/- 42.87 vs. 12.53 +/- 4.05 ng/ml; p < 0.001). PT, although still in the normal range, was prolonged in patients with hyperprolactinemia as compared to the control group (13.53 +/- 1.39 vs. 12.65 +/- 0.53 s; p = 0.03) and normalized after therapy (12.69 +/- 0.65 vs. 12.65 +/- 0.53 s; p = 0.88). TT, although in normal range, was significantly shorter in the hypeprolactinemic patients than in the controls (14.34 +/- 4.52 vs. 17.21 +/- 1.35 s; p < 0.025) and after treatment remained significantly shorter than in the controls (15.17 +/- 1.55 vs. 17.21 +/- 1.35 s; p < 0.0001). D-dimer values before treatment in the patients with hyperproplactinemia were above the normal range (239.47 +/- 107.93 vs. 131.27 +/- 50.64 ng/ml, p = 0.002) and decreased to normal values after therapy (239.47 +/- 107.93 vs. 146.60 +/- 39.15 ng/ml; p < 0.001). D-dimer levels correlated with PRL (r = 0.30) and the change in serum D-dimer values significantly correlated with the change in PRL levels during therapy (r = 0.62). aPTT, vWFAg and fibrinogen were similar in patients and controls.
  
  
  CONCLUSIONS
  In our study, increased thrombin generation that resulted in elevated D-dimer levels may be one of the contributing factors to the prethrombotic state in patients with hyperprolactinemia.
authors.forename: Milica
authors.initials: M
authors.lastname: Medić-Stojanoska
authors.forename: Gorana
authors.initials: G
authors.lastname: Mitić
authors.forename: Igor
authors.initials: I
authors.lastname: Mitić
authors.forename: Dragan T
authors.initials: DT
authors.lastname: Spasić
authors.forename: Nikola
authors.initials: N
authors.lastname: Curić
authors.forename: Sandra
authors.initials: S
authors.lastname: Pekić
authors.forename: Branka
authors.initials: B
authors.lastname: Kovacev-Zavisić
authors.forename: Vera
authors.initials: V
authors.lastname: Popović
mesh_terms: D000328:Adult; D001777:Blood Coagulation / Q000502:physiology*; D001780:Blood Coagulation Tests; D016022:Case-Control Studies; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D006487:Hemostasis; D006801:Humans; D006966:Hyperprolactinemia / Q000097:blood* / Q000150:complications; D010314:Partial Thromboplastin Time; D010911:Pituitary Neoplasms / Q000097:blood* / Q000150:complications; D015175:Prolactinoma / Q000097:blood* / Q000150:complications; D011517:Prothrombin Time; D055815:Young Adult
chemical_list: D005338:Fibrin Fibrinogen Degradation Products; C036309:fibrin fragment D; D005340:Fibrinogen